AngioDynamics (NASDAQ:ANGO - Get Free Report) released its quarterly earnings results on Tuesday. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09, RTT News reports. The firm had revenue of $80.16 million during the quarter, compared to analysts' expectations of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The firm's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.06) EPS. AngioDynamics updated its FY 2026 guidance to -0.350--0.250 EPS.
AngioDynamics Price Performance
Shares of NASDAQ:ANGO traded down $0.04 during trading hours on Friday, hitting $8.71. The company's stock had a trading volume of 431,139 shares, compared to its average volume of 590,716. AngioDynamics has a 52 week low of $5.83 and a 52 week high of $13.50. The company has a market capitalization of $353.51 million, a price-to-earnings ratio of -10.49 and a beta of 0.60. The firm's fifty day moving average price is $9.88 and its 200 day moving average price is $10.07.
Analysts Set New Price Targets
ANGO has been the subject of several research reports. Canaccord Genuity Group set a $17.00 price objective on shares of AngioDynamics and gave the company a "buy" rating in a research report on Wednesday. Lake Street Capital initiated coverage on shares of AngioDynamics in a research report on Wednesday. They issued a "buy" rating and a $24.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday.
View Our Latest Analysis on AngioDynamics
Institutional Investors Weigh In On AngioDynamics
An institutional investor recently raised its position in AngioDynamics stock. Goldman Sachs Group Inc. grew its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 9.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 259,226 shares of the medical instruments supplier's stock after purchasing an additional 22,658 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.64% of AngioDynamics worth $2,434,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 89.43% of the company's stock.
AngioDynamics Company Profile
(
Get Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
See Also
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
